RE:why blackrock, and others, are considering cxr....I believe they can be bought out at a premium from todays price but how much is the question. The problem is the huge debt and the fact they overpaid dramatically for their last purchases. Legacy pharma assets can be bought for 5-6 times ebitda in todays market from larger companies disposing of them. The infrasture of the company is certainly worth something but it hasn't been thrown together for long enough to realize any meaningfull synergies. A company like blackrock could literally buy a bunch of individual drugs in decline at 5-6 times ebitda and achieve the same end paying half as much but with a few bumps throwing it all together. I'm convinced this is why smart money is staying away for now.
bull_man wrote: for example, blackrock trading at an 18x multiple; cxr trading at a deep discount, somewhere between 3x and 4x; take out any cxr no longer needed administrative fat plus merger synergies and cxr multiple decreases even further; basically, a cash cow for blackrock, or other suitors; looks like the $45US talked about on this board or approximately $60CDN is would still be a steal for any acquiring company; i hope you fcking shorters take it up the a$$; what a bunch of low-life excuses for human beings you all are.